BGI Genomics' low ROE and net income growth are worrisome. D...
BGI Genomics' low ROE and net income growth are worrisome. Despite high reinvestment, the low ROE indicates that it's not benefiting investors and is hampering earnings growth. Caution is advised due to these factors.
Are BGI Genomics Co., Ltd.'s (SZSE:300676) Mixed Financials Driving The Negative Sentiment?
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment